Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients…
By H. Kantarjian, X. Thomas, A. Dmoszyńska, A. Wierzbowska, G. Mazur, J. Mayer, J. Gau, W. Chou, R. Buckstein, J. Čermák and 8 more. Journal of Clinical Oncology, 2012
1,059 citations recorded by the source corpus.
Subfields: Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/009fda6ffb4b5379ca8784410eee8a93ce754e6c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, methodology): “0 months) was observed.(213) The AZA-AML-001 trial compared azacitidine with 3 conventional care regimens in patients aged $65 yearswith.”
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017, neutral): “Age, median (range), y 67 (19-100) 67 (19-100) 70 (19-100)”
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. (2015, methodology): “Decitabine was evaluated in a trial with 485 patients age$65 years with AML and$20% BM blasts randomly assigned to receive either decitabine or physicians’ choice of treatment (LDAC or BSC).(4) The primary analysis for that trial demonstrated a nonsignificant survival increasewith decitabine (7.”